Therapeutic Uses Of Monoclonal Antibodies To The Angiotensin-II Type 1 Receptor
AssigneeQueen Mary & Westfield College, University of London
InventorsStewart Barker, John Richard Puddefoot, Gavin Paul Vinson
Life of this patent
Estimating the term…
Abstract
The use of monoclonal antibodies to the angiotensin-II type-I receptor is provided for the treatment of cancer and vascular smooth muscle cell proliferation. Specifically, use is provided of a monoclonal antibody or a fragment thereof to a peptide comprising the N-terminal portion of the angiotensin-II type-1 receptor defined by the sequence MILNSSTEDG IKRIQDDCPK AGHRHNYIFVM IPTLYSIIFV VGIFG in the preparation of a medicament for the treatment of cancer or in the preparation of a medicament for the treatment of vascular smooth muscle (VSM) cell proliferation.
Claims20
1-11. (canceled)
A composition comprising a peptide sequence comprising the N-terminal portion of the angiotensin-II type-1 receptor defined by the sequence MILNSSTEDG IKRIQDDCPK AGRHNYIFVM IPTLYSIIFV VGIFG (SEQ ID NO:1) or a fragment thereof comprising at least five amino acid residues.
A method of treating cancer comprising administering to a subject in need thereof a therapeutically effective amount of a monoclonal antibody, or a fragment thereof, that binds to a peptide;
- wherein the peptide comprises an N-terminal portion of an angiotensin-II type-1 receptor comprising the sequence MILNSSTEDG IKRIQDDCPK AGRHNYIFVM IPTLYSIIFV VGIFG (SEQ ID NO:1), a conservative mutant thereof, or an active fragment thereof comprising at least five amino acid residues.
A method of treating a disease or condition associated with vascular smooth muscle cell proliferation comprising administering to a subject in need thereof a therapeutically effective amount of a monoclonal antibody, or a fragment thereof, that binds to a peptide;
- wherein the peptide comprises an N-terminal portion of an angiotensin-II type-1 receptor comprising the sequence MILNSSTEDG IKRIQDDCPK AGRHNYIFVM IPTLYSIIFV VGIFG (SEQ ID NO:1), a conservative mutant thereof, or an active fragment thereof comprising at least five amino acid residues.
A composition comprising a peptide comprising up to 45 amino acids, and comprising the sequence EDGIKRIQDD (SEQ ID NO:2).
Dependencies are inferred from the claim text.